ASCO 2019 Novel targetedantibody treatment produced responses in nearly half of patients with advanced urothelial cancer

ASCO 2019: Novel targeted-antibody treatment produced responses in nearly half of patients with advanced urothelial cancer

10:09 EDT 3 Jun 2019 | ecancermedicalscience

A single arm, phase II clinical trial of 125 patients showed treatment with enfortumab vedotin (EV) – a new agent targeting Nectin-4, a protein found in 97% of urothelial cancers – produced responses in 44% of patients with locally advanced or...

More From BioPortfolio on "ASCO 2019: Novel targeted-antibody treatment produced responses in nearly half of patients with advanced urothelial cancer"